Natera (NASDAQ:NTRA) Price Target Raised to $230.00

Natera (NASDAQ:NTRA) had its price target raised by Piper Sandler from $220.00 to $230.00 in a report published on Tuesday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the medical research company’s stock.

A number of other analysts have also weighed in on NTRA. Cowen restated a “buy” rating on shares of Natera in a research note on Friday, August 8th. JPMorgan Chase & Co. raised their target price on Natera from $210.00 to $240.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Barclays increased their target price on Natera from $210.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Evercore ISI boosted their price target on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Fifteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $216.65.

Natera Price Performance

NASDAQ NTRA opened at $200.67 on Tuesday. Natera has a 52-week low of $125.38 and a 52-week high of $212.21. The firm has a market capitalization of $27.69 billion, a price-to-earnings ratio of -87.63 and a beta of 1.75. The company’s fifty day moving average is $180.78 and its two-hundred day moving average is $165.22.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s revenue was up 34.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.26) earnings per share. As a group, sell-side analysts expect that Natera will post -1.49 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $159.99, for a total value of $479,970.00. Following the completion of the transaction, the insider owned 117,559 shares of the company’s stock, valued at $18,808,264.41. This trade represents a 2.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 160,703 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the transaction, the chief executive officer owned 144,816 shares in the company, valued at $28,957,407.36. This represents a 52.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 223,336 shares of company stock valued at $42,990,633 over the last three months. Corporate insiders own 5.63% of the company’s stock.

Hedge Funds Weigh In On Natera

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of Jackson Hole Trust bought a new stake in Natera in the first quarter valued at approximately $29,000. Hilltop National Bank bought a new position in shares of Natera during the 2nd quarter worth approximately $33,000. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Natera during the 2nd quarter worth approximately $36,000. Sound Income Strategies LLC raised its stake in Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares during the period. Finally, TCTC Holdings LLC raised its stake in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 124 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.